JP2025509828A5 - - Google Patents

Info

Publication number
JP2025509828A5
JP2025509828A5 JP2024555341A JP2024555341A JP2025509828A5 JP 2025509828 A5 JP2025509828 A5 JP 2025509828A5 JP 2024555341 A JP2024555341 A JP 2024555341A JP 2024555341 A JP2024555341 A JP 2024555341A JP 2025509828 A5 JP2025509828 A5 JP 2025509828A5
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
promoter
expression
raav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509828A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064673 external-priority patent/WO2023178339A2/en
Publication of JP2025509828A publication Critical patent/JP2025509828A/ja
Publication of JP2025509828A5 publication Critical patent/JP2025509828A5/ja
Pending legal-status Critical Current

Links

JP2024555341A 2022-03-18 2023-03-18 ウイルスベクターによるtnnt2関連心筋症を処置するための方法および組成物 Pending JP2025509828A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263321264P 2022-03-18 2022-03-18
US63/321,264 2022-03-18
PCT/US2023/064673 WO2023178339A2 (en) 2022-03-18 2023-03-18 Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector

Publications (2)

Publication Number Publication Date
JP2025509828A JP2025509828A (ja) 2025-04-11
JP2025509828A5 true JP2025509828A5 (https=) 2026-03-27

Family

ID=88024553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555341A Pending JP2025509828A (ja) 2022-03-18 2023-03-18 ウイルスベクターによるtnnt2関連心筋症を処置するための方法および組成物

Country Status (8)

Country Link
US (1) US20250195694A1 (https=)
EP (1) EP4493702A4 (https=)
JP (1) JP2025509828A (https=)
KR (1) KR20250007509A (https=)
AU (1) AU2023234604A1 (https=)
CA (1) CA3254775A1 (https=)
IL (1) IL315697A (https=)
WO (1) WO2023178339A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025214477A1 (en) * 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors
WO2025226841A1 (en) * 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2025235807A1 (en) * 2024-05-10 2025-11-13 Solid Biosciences, Inc. Compositions and methods to improve graft survival

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5553547B2 (ja) * 2009-07-14 2014-07-16 俊一 梶岡 トロポニン含有医薬組成物
US9783805B2 (en) * 2013-02-28 2017-10-10 City Of Hope Replication capable rAAV vectors encoding inhibitory siRNA and methods of their use
EP2792742A1 (en) * 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
US20210363193A1 (en) * 2018-04-27 2021-11-25 Universität Heidelberg Modified aav capsid polypeptides for treatment of muscular diseases
WO2020198337A1 (en) * 2019-03-25 2020-10-01 Ohio State Innovation Foundation Engineered mrna sequences and uses thereof
EP3947700A4 (en) * 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
EP3997227A1 (en) * 2019-07-10 2022-05-18 Locanabio, Inc. Rna-targeting knockdown and replacement compositions and methods for use
WO2021154923A2 (en) * 2020-01-29 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
WO2021163357A2 (en) * 2020-02-13 2021-08-19 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
CA3242351A1 (en) * 2021-12-10 2023-06-15 University Of Florida Research Foundation, Incorporated Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector

Similar Documents

Publication Publication Date Title
JP2025509828A5 (https=)
US20220331409A1 (en) Factor ix gene therapy
JP2024545183A5 (https=)
JP2024545186A5 (https=)
AU2017250791A1 (en) Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
JP2023504773A5 (https=)
JP2022512589A5 (https=)
JP2021533126A (ja) 臓器機能を制御するための遺伝子治療方法
JP2024515459A5 (https=)
JP2024546103A5 (https=)
JP2024513907A5 (https=)
US11077208B2 (en) Wilson's disease gene therapy
CN114276419B (zh) 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
CN113121651B (zh) 低中和抗体腺相关病毒衣壳蛋白
JP2024503091A5 (https=)
JP2024527742A5 (https=)
CN113121654B (zh) 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体
US12415850B2 (en) Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
JP2023526923A5 (https=)
JP2023534647A5 (https=)
WO2021169167A1 (en) Method for treating coronavirus infections
JP2022530264A5 (https=)
US20250066437A1 (en) Transgenic expression cassette for treating muscular dystrophy
CN112961220B (zh) 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体
JP2025510946A5 (https=)